IP Library › Granted Patent US 9,243,237
Granted Patent B2
US 9,243,237 · App. 13/881,974 · Granted Jan 26, 2016

Method for mass production of factor VII/VIIA

Inventors: Chang Hwan Kim (Suwon-si, KR); Sung Kap Hong (Yongin-si, KR); Byung Sun Lee (Seoul, KR); Sung Hwan Hong (Seoul, KR); Se Chang Kwon (Seoul, KR)
Assignee: HANMI SCIENCE CO., LTD
C12N9/6437C07K14/745
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,243,237
App. No.
13/881,974
Granted
Jan 26, 2016
Kind
B2
Abstract

A method for the mass production of human coagulation Factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation Factor VII gene operably linked thereto; b) obtaining a transformed host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation Factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells.

Claims (13)

1. A method for mass production of human coagulation

Factor VII, comprising:

a) providing a Chinese hamster ovarian carcinoma cell line transfected with an expression vector, said expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCCC repeat sequences from the GC-rich region and a dihydrofolate reductase gene operably linked thereto and ii) a cytomegalovirus promoter and a human coagulation Factor VII gene operably linked thereto;

b) culturing the transfected cell line of step a) in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation Factor VII;

c) culturing the selected cells in a medium containing sodium butyrate in concentration from 1 mM to 1.5 mM to produce human coagulation Factor VII; and

d) harvesting the produced human coagulation Factor VII, wherein the human coagulation Factor VII gene has the nucleotide sequence of SEQ ID NO: 3.

2. The method of claim 1 , wherein the GC-rich region contains as many as or less than one CCGCCC repeating sequence.

3. The method of claim 1 , wherein the expression vector is pXOGC-FVII.

4. The method of claim 1 , wherein the Chinese hamster ovarian carcinoma cell line before transfection in step a), is devoid of dihydrofolate reductase gene.

5. The method of claim 1 , wherein the selected cells of step c) is HMF708, which has Accession Number KCTC 11779BP.

6. The method of claim 1 , further comprising purifying the human coagulation Factor VII.

7. The method of claim 1 , further comprising activating the human coagulation Factor VII.

8. A cell line for producing human coagulation Factor VII, wherein said cell line is HMF708 having Accession Number KCTC 11779BP.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: KIM, CHANG HWAN; HONG, SUNG KAP; LEE, BYUNG SUN; HONG, SUNG HWAN; KWON, SE CHANG
To: HANMI SCIENCE CO., LTD.
Reel/Frame 030764/0720 →
Priority Claims (1)
KR 10-2010-0104403 · Oct 26, 2010 · national
Continuity (1)
Related Publication 20130273634A1 · Oct 17, 2013